ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 602

Improvements in Work Productivity with up to 104 Weeks of Apremilast Monotherapy: Results from a Phase 3b, Randomized, Controlled Study in Biologic-NaïVe Subjects with Active Psoriatic Arthritis

Philip J Mease1, Dafna D Gladman2, Eric K Davenport3, Xiaolei Zhou3, Benoit Guerette4, Lichen Teng4, Satyin Kaura4 and Peter Nash5, 1Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, 2Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3RTI Health Solutions, Research Triangle Park, NC, 4Celgene Corporation, Summit, NJ, 5University of Queensland, Brisbane, Australia

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with active psoriatic arthritis (PsA) may experience disease manifestations across multiple domains, as well as impaired functioning in daily activities at home and at work. ACTIVE, a phase 3b study, is evaluating the efficacy of apremilast (APR) monotherapy in biologic-naïve subjects with PsA who may have had exposure to 1 prior conventional disease-modifying anti-rheumatic drug. The ACTIVE work productivity findings through Week 104 are reported.

Methods: Subjects were randomized (1:1) to receive APR 30 mg BID or placebo. Subjects who did not improve at least 10% in both swollen and tender joint counts at Week 16 were eligible for early escape. At Week 24, all remaining placebo subjects were switched to APR. Work productivity and activity impairment were assessed at baseline and Week 16 using the 6-item, self-administered Work Productivity and Activity Impairment Questionnaire: Psoriatic Arthritis (WPAI:PsA). The WPAI:PsA includes 4 subscale scores: Absenteeism, Presenteeism, Work Productivity Loss, and Activity Impairment; subscale scores each range from 0% to 100%, with higher scores indicating greater impairment. Work-related subscales were evaluated only among employed subjects, while activity impairment was evaluated among all subjects, regardless of employment. Correlations were examined at Week 16 between WPAI:PsA subscale scores and selected 36-item Short-Form Health Survey version 2 (SF-36v2) domain scores (i.e., Physical Functioning [PF], Bodily Pain [Pain], and Vitality [VIT]). Improvement in work productivity was assessed through Week 104.

Results: Baseline characteristics were similar between the APR and placebo subjects with WPAI:PsA scores included in the current analysis. At Week 16, APR significantly improved work productivity and the ability to carry out daily activities compared with placebo, with significantly greater mean improvements observed in the overall Work Productivity Loss score (P=0.001) and Activity Impairment score (P<0.001) (Table). Estimated mean change in the Absenteeism score was similar with APR vs. placebo (P=0.679). By contrast, the Presenteeism score showed significant improvement with APR vs. worsening with placebo (−10.8% vs. 4.1%; P=0.002). At Week 16, statistically significant correlations were observed between WPAI:PsA subscale scores (except Absenteeism) and SF-36v2 domain scores (i.e., PF, Pain, and VIT). Among subjects randomized to receive APR at baseline, Week 16 WPAI:PsA subscale score improvements were generally maintained through Week 104.

Conclusion: In biologic-naïve subjects with active PsA, APR monotherapy contributed to an overall improvement in work productivity at Week 16, which correlated with SF-36v2 PF, Pain, and VIT scores; improvements in WPAI:PsA subscale scores were generally maintained to Week 104.


Disclosure: P. J. Mease, Celgene, Novartis, AbbVie, Amgen, BMS, Lilly, Pfizer and UCB, 2,Celgene, Corrona, Novartis, AbbVie, Amgen, BMS, Crescendo, Genentech, Janssen, Lilly, Merck, Pfizer and UCB, 5,AbbVie, Amgen, BMS, Crescendo, Celgene, Genentech, Janssen, Pfizer and UCB, 8; D. D. Gladman, Abbvie, 2,Amgen, 2,Celgene, 2,BMS, 2,Janssen Pharmaceutica Product, L.P., 2,Eli Lilly and Company, 5,Novartis Pharmaceutical Corporation, 2,Pfizer Inc, 2,UCB, 2; E. K. Davenport, None; X. Zhou, None; B. Guerette, Celgene Corporation, 3; L. Teng, Celgene Corporation, 3; S. Kaura, Celgene Corporation, 3; P. Nash, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Hospira, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi, and UCB, 5,AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Hospira, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi, and UCB, 8,AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Hospira, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi, and UCB, 2.

To cite this abstract in AMA style:

Mease PJ, Gladman DD, Davenport EK, Zhou X, Guerette B, Teng L, Kaura S, Nash P. Improvements in Work Productivity with up to 104 Weeks of Apremilast Monotherapy: Results from a Phase 3b, Randomized, Controlled Study in Biologic-NaïVe Subjects with Active Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/improvements-in-work-productivity-with-up-to-104-weeks-of-apremilast-monotherapy-results-from-a-phase-3b-randomized-controlled-study-in-biologic-naive-subjects-with-active-psoriatic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improvements-in-work-productivity-with-up-to-104-weeks-of-apremilast-monotherapy-results-from-a-phase-3b-randomized-controlled-study-in-biologic-naive-subjects-with-active-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology